Fertility preservation in women with ovarian cancer: Finding new pathways: A case-control study

Publish Year: 1399
نوع سند: مقاله ژورنالی
زبان: English
View: 218

This Paper With 10 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_IJRM-19-2_006

تاریخ نمایه سازی: 17 فروردین 1400

Abstract:

Background: Surgery and chemotherapy are the two most common treatments for cancers, including ovarian cancer. Although most ovarian cancers occur over the age of 45 yr, it may involve younger women and affect their reproductive ability. Objective: To assess the expression of Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), Forkhead Box O1 (FOXO1), and miR-340 genes in the ovarian cancer tissues as well as ovarian cancer cell lines. Materials and Methods: In this case-control study, 30 ovarian cancer samples (with the average age of 37 ± 2.5 years) coupled with their non-tumor marginal tissue (as a control) were collected. Proliferated cell lines were treated with several concentrations of cisplatin, and the half maximal inhibitory concentration (IC50) of cisplatin was quantified by MTT-assay. After RNA extraction, cDNA synthesis and qRT-PCR were done. Finally, the results were analyzed. Results: While the expression levels of miR-340 and FOXO1 genes in tumor samples displayed a significant reduction (p ≤ 0.001), the LGR5 gene presented a significant increase in expression (p ≤ 0.0001). However, conversely, the expression levels of miR-340 and FOXO1 genes in cisplatin-sensitive cell lines, after 24, 48, and 72 hr of cisplatin treatment, indicated a significant increase (p ≤ 0.001) while the expression of LGR5 gene showed a significant decrease in the cisplatin-sensitive cell line (p < 0.05). Conclusion: The LGR5, FOXO1, and miR-340 genes can be targeted for early diagnosis and more accurate treatment of ovarian cancer and may prevent some of the ovarian cancer complications such as infertility.

Authors

Ali Khodadadian

Department of Medical Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Yasser Varghaiyan

Department of Immunology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Emad Babakhanzadeh

Department of Medical Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Iraj Alipourfard

Center of Pharmaceutical Sciences, Faculty of Life Sciences, University of Vienna, Vienna, Austria. School of Pharmacy, Faculty of Sciences, University of Rome Tor Vergata, Rome, Italy.

Saeed Haghi-Daredeh

Department of Medical Nanotechnology, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.

Amin Ghobadi

Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

Mohsen Hemmati-Dinarvand

Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Mehrdad Talebi

Department of Medical Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Nasrin Ghasemi

Abortion Research Centre, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Wang Y, Sheng Q, Spillman MA, Behbakht K, Gu H. ...
  • Berry NB, Bapat SA. Ovarian cancer plasticity and epigenomics in ...
  • Hancke K, Isachenko V, Isachenko E, Weiss JM. Prevention of ...
  • Gaffan J, Holden L, Newlands ES, Short D, Fuller S, ...
  • Kerr JB, Hutt KJ, Cook M, Speed TP, Strasser A, ...
  • Hseu Y-C, Lin Y-C, Rajendran P, Thigarajan V, Mathew DC, ...
  • Kobayashi S, Yamada‐Okabe H, Suzuki M, Natori O, Kato A, ...
  • Wachtel M, Schafer BW. PAX3-FOXO1: Zooming in on an "undruggable" ...
  • Zhao Y, Tindall DJ, Huang H. Modulation of androgen receptor ...
  • Choi Y, Park J, San Ko Y, Kim Y, Pyo ...
  • Vallvé-Juanico J, Barón C, Suárez-Salvador E, Castellví J, Ballesteros A, ...
  • Vallvé-Juanico J, Suárez-Salvador E, Castellví J, Ballesteros A, Taylor HS, ...
  • Vasquez YM, Wang X, Wetendorf M, Franco HL, Mo Q, ...
  • Ting AY, Zelinski MB. Characterization of FOXO1, 3 and 4 ...
  • Karami N, Mirabutalebi SH, Montazeri F, Kalantar SM, Sheikhha MH, ...
  • Khodadadian A, Hemmati-Dinarvand M, Kalantary-Charvadeh A, Ghobadi A, Mazaheri M. ...
  • Mirabutalebi SH, Karami N, Montazeri F, Fesahat F, Sheikhha MH, ...
  • Shi S, Chen X, Liu H, Yu K, Bao Y, ...
  • Park J, Choi Y, San Ko Y, Kim Y, Pyo ...
  • Zhang L, Guo X, Zhang D, Fan Y, Qin L, ...
  • Shi L, Chen ZG, Wu LL, Zheng JJ, Yang JR, ...
  • Song L, Duan P, Gan Y, Li P, Zhao C, ...
  • Gao Zh, Liu R, Ye N, Liu Ch, Li X, ...
  • Shi S, Chen X, Liu H, Yu K, Bao Y, ...
  • Cao HZ, Liu XF, Yang WT, Chen Q, Zheng PS. ...
  • Vasquez YM, Wang X, Wetendorf M, Franco HL, Mo Q, ...
  • Park J, Choi Y, San Ko Y, Kim Y, Pyo ...
  • Rezaei Z, Sebzari A, Kordi-Tamandani DM, Dastjerdi K. Involvement of ...
  • Schuldes H, Bade S, Knobloch J, Jonas D. Loss of ...
  • https://doi.org/10.1002/(SICI)1097-0142(19970501)79:93.0.CO;2- ...
  • نمایش کامل مراجع